Publication: Expression of a neu,c-erbB-2-like product in neuroendocrine cells of mammals
Loading...
Date
2000
Authors
Martin Lacave, Inés ; Utrilla, J.C.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The neulc-erbB-2 oncogen encodes a 185
kDa protein closely homologous to the epidermal growth
factor receptor. The protein product (p185) is a glycoprotein
with an external domain and an internal domain
with tyrosine kinase activity. Amplification and/or
overexpression of p185 is related to several human
adenocarcinomas. Subsequent studies demonstrated its
presence in certain neuroendocrine (NE) neoplasms,
including phaeochromocytomas. insulinomas and
medullary thyroid carcinomas. However, relatively little
is known about its role in normal cell growth regulation
and development. Therefore, our objetive was to
determine whether neulc-erbB-2 was expressed in
normal NE tissues of different mammals, specially in
humans, as it was in their neoplasms. We have examined
by immunohistochemistry different endocrine glands
(thyroid, pancreas, suprarrenal and hypophysis) and the
small intestine of human beings, rats and guinea pigs,
using two polyclonal antibodies raised against the
intracytoplasmic part of the protein, and specific antigen
absorption controls. We have found that a neulc-erbB-2-
like product occurs in all normal NE tissues examined: C
cells of the thyroid gland, chromaffin cells of the adrenal
medulla, pancreatic islets, enteroendocrine cells of the
small intestine and, finally, scattered cells of the
adenohypophysis, according to a typical granular
immunohistochemical pattern. Our results indicate that
normal NE cells share a new common antigen in their
cytoplasms, a neulc-erbB-2-like product, with a similar
immunostaining pattern to that presented by the
neoplasms derived from them.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.